litlas
Log inCreate account

Andrew Wardley

Active 1997–2023

61
Papers
18,477
Citations
47
h-index
61
i10-index

Citations

Citations per year for Andrew Wardley1974: 2 citations1993: 2 citations1997: 1 citations1998: 4 citations1999: 4 citations2000: 6 citations2001: 4 citations2002: 12 citations2003: 9 citations2004: 13 citations2005: 21 citations2006: 32 citations2007: 52 citations2008: 95 citations2009: 112 citations2010: 156 citations2011: 229 citations2012: 196 citations2013: 198 citations2014: 176 citations2015: 179 citations2016: 187 citations2017: 172 citations2018: 161 citations2019: 388 citations2020: 534 citations2021: 582 citations2022: 630 citations2023: 505 citations2024: 590 citations2025: 319 citations2026: 8 citations1975–1992: no citations, so these years are not shown1994–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,091 citing papers, 22.7% of this breakdownUnited Kingdom: 715 citing papers, 7.8% of this breakdownItaly: 688 citing papers, 7.5% of this breakdownChina: 687 citing papers, 7.5% of this breakdownGermany: 467 citing papers, 5.1% of this breakdownFrance: 409 citing papers, 4.4% of this breakdownSpain: 384 citing papers, 4.2% of this breakdownCanada: 383 citing papers, 4.2% of this breakdownSwitzerland: 288 citing papers, 3.1% of this breakdownBelgium: 285 citing papers, 3.1% of this breakdownAustralia: 282 citing papers, 3.1% of this breakdownJapan: 236 citing papers, 2.6% of this breakdown
0%22.7%Other 24.7%

Institutions

Fields

  • Medicine65.6%
  • Biochemistry, Genetics and Molecular Biology29.9%
  • Immunology and Microbiology1.1%
  • Engineering0.6%
  • Materials Science0.6%
  • Computer Science0.4%
  • Other1.8%

Topics

  • HER2/EGFR in Cancer Research9%
  • Breast Cancer Treatment Studies7.6%
  • Advanced Breast Cancer Therapies7.4%
  • PARP inhibition in cancer therapy4.7%
  • Cancer Treatment and Pharmacology4%
  • Cancer Genomics and Diagnostics4%
  • Other63.3%

Coauthors

All papers

Open in search
  1. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Authors: Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortés, Jens Huober, Andrew Wardley, Sara M. Tolaney, Irfan Cicin, Ian C. Smith, Martin Frenzel, Desirée Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O’Shaughnessy, Priya Rastogi - Journal of Clinical Oncology 2020 cited by 986

  2. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    Authors: David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın and 68 more - Annals of Oncology 2021 cited by 729

  3. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

    Authors: Nicholas C. Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley, Matthew Beaney, Lisa Fox, Kate Goddard, Isaac García-Murillas, Paula Proszek, Peter S Hall, Catherine Harper‐Wynne, Tamas Hickish, Sarah Kernaghan, Iain R. Macpherson, Alicia Okines, Carlo Palmieri, Sophie Perry, Kat Randle, Claire Snowdon, Hilary Stobart, Andrew Wardley, Duncan Wheatley, Simon Waters, Matthew Winter, Michael Hubank, Steven Allen, Judith M. Bliss, Shing Leng Chan, Anne Armstrong, F. Raja, Peter Schmid, Andrew Tutt, René L. Roux, Susan Cleator - Annals of Oncology 2022 cited by 191

  4. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    Authors: Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer - Journal of Clinical Oncology 2020 cited by 549

  5. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

    Authors: Nicholas C. Turner, Belinda Kingston, Lucy Kilburn, Sarah Kernaghan, Andrew Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew Winter, Hannah Bye, Michael Hubank, Heidrun Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer M. Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M. Bliss, Alistair Ring - The Lancet Oncology 2020 cited by 352

  6. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial

    Authors: Sarah E. Pinder, S. Kernaghan, G. Wilson, Andrew Wardley, J.M. Flanagan, M.Q. Hatton, P. Gazinska, R. Brown, K.M. Timms, P. Ellis, Charles M. Perou, R. Roylance, Maggie C.U. Cheang, C. Harper-Wynne, Percy Parker, Peter Barrett‐Lee, I.E. Smith, M. Dowsett, C. Gillett, S. Chan, J.M. Bliss, J. Parikh, Lucy Kilburn, A. Ashworth, J. Owen, M. LL. HARRIES, N. Rahman, J. Abraham, S. Barrett, Katherine A. Hoadley, A. Shaw, H. Tovey, A. Gutin, Vandna Shah, Andrew Tutt, A. Grigoriadis, Levi Fox, J.S. Lanchbury - Nature Medicine 2018 cited by 903

  7. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Authors: Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney, Zhimin Shao, Peter A. Fasching, Chiun‐Sheng Huang, Georgina Garnica Jaliffe, A. Tryakin, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Mariette Andersson, Kenji Tamura, Lucia Del Mastro, Guenther G. Steger, Hans Kreipe, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Valérie André, Ran Wei, Susana Barriga, S. Sherwood, Tammy Forrester, Montserrat Muñoz-Mateu, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 cited by 378

  8. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

    Authors: Sara M. Tolaney, Andrew Wardley, Stefania Zambelli, John Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci, Seock‐Ah Im, Sung‐Bae Kim, Stephen Johnston, Arlene Chan, Shom Goel, Kristen Catron, Sonya C. Chapman, Gregory L. Price, Zhengyu Yang, M. Corona Gainford, Fabrice André - The Lancet Oncology 2020 cited by 261

  9. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

    Authors: Andrew Tutt, Mark E. Robson, Judy E. Garber, Susan M. Domchek, M. William Audeh, Jeffrey N. Weitzel, Michael Friedländer, Banu Arun, Niklas Loman, Rita K. Schmutzler, Andrew Wardley, Gillian Mitchell, Helena Earl, Mark Wickens, James Carmichael - The Lancet 2010 cited by 1,636

  10. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

    Authors: Françoise Rothé, Maria João Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela D. Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, José Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah‐Jane Dawson, Michail Ignatiadis - Clinical Cancer Research 2019 cited by 127

  11. Genomic profile of advanced breast cancer in circulating tumour DNA

    Authors: Belinda Kingston, Rosalind Cutts, Hannah Bye, Matthew Beaney, Giselle Walsh-Crestani, Sarah Hrebien, Claire Swift, Lucy Kilburn, Sarah Kernaghan, Laura Moretti, Katie Wilkinson, Andrew Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Jorge S. Reis‐Filho, Michael Hubank, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac García-Murillas, Judith M. Bliss, Alistair Ring, Nicholas C. Turner - Nature Communications 2021 cited by 95

  12. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

    Authors: Maria Coakley, Guillermo Villacampa, Prithika Sritharan, Claire Swift, Kathryn Dunne, Lucy Kilburn, Katie Goddard, Christodoulos Pipinikas, Patricia Rojas, Warren Emmett, Peter S Hall, Catherine Harper‐Wynne, Tamas Hickish, Iain R. Macpherson, Alicia Okines, Andrew Wardley, Duncan Wheatley, Simon Waters, Carlo Palmieri, Matthew Winter, Rosalind Cutts, Isaac García-Murillas, Judith M. Bliss, Nicholas C. Turner - Clinical Cancer Research 2023 cited by 44

  13. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

    Authors: Bella Kaufman, John R. Mackey, Michael Clemens, P. P. Bapsy, Ashok K. Vaid, Andrew Wardley, Sergei Tjulandin, Michaela K. Jahn, Michaela Lehle, A. Feyereislova, Cédric Révil, Alison Jones - Journal of Clinical Oncology 2009 cited by 850

  14. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer

    Authors: Antonio Llombart‐Cussac, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel Gil‐Gil, Manuel Ruíz‐Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Serena Di Cosimo, Joseph Gligorov, Andreas Schneeweiß, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez-De Dueñas, Kepa Amillano, Andrea Malfettone, Javier Cortés, Antonio Antón, Vladimir Moiseyenko, Paul Cottu, Gemma Viñas, Thierry Petit, Petra Tesařová, Vladimir Vladimirov, Juan Cueva Bañuelos, Marco Colleoni, Gianfilippo Bertelli, Pascuala Garcı́a-Martı́nez, R. Andrés, Tatiana Barannikova, Sònia Servitja, Jacques Médioni, Saverio Cinieri, Juan Bayo, Santiago González, Bohuslav Melichar, Vicente Caranyana, Francesco Atzori, Mark Beresford, Steven T. F. Chan, Maria Luque-Cabal, Juan de la Haba-Rodríguez, Joachim Bischoff, Guzel Mukhametsina, Maria Cazzaniga, Daniele Generali, Andrew Wardley, Laura Cortesi, Luigi Cavanna, Mario Airoldi - JAMA Oncology 2021 cited by 106

  15. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Authors: David Miles, Arlene Chan, Luc Dirix, Javier Cortés, Xavier Pivot, Piotr Tomczak, T. Delozier, Joohyuk Sohn, Louise Provencher, Fabio Puglisi, Nadia Harbeck, Guenther G. Steger, Andreas Schneeweiß, Andrew Wardley, A. Chlistalla, Gilles Romieu - Journal of Clinical Oncology 2010 cited by 887

  16. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    Authors: Nancy U. Lin, Véronique Dièras, Devchand Paul, Dominique Lossignol, Christos Christodoulou, Hans‐Joachim Stemmler, Henri Roché, Minetta C. Liu, Richard Greil, Eva Ciruelos, Sibylle Loibl, Stefania Gori, Andrew Wardley, Denise A. Yardley, Adam Brufsky, Joanne L. Blum, Stephen D. Rubin, B. Dharan, Klaudia Steplewski, Denise Zembryki, Cristina Oliva, Debasish Roychowdhury, Paolo Paoletti, Eric P. Winer - Clinical Cancer Research 2009 cited by 663

  17. Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

    Authors: José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada - Journal of Clinical Oncology 2013 cited by 351

  18. Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

    Authors: R. Charles Coombes, Holly Tovey, Lucy Kilburn, Janine Mansi, Carlo Palmieri, John M.S. Bartlett, Jonathan Hicks, Andreas Makris, Abigail Evans, Sibylle Loibl, Carsten Denkert, Elisabeth Murray, Robert Grieve, Robert E. Coleman, Annabel Borley, Marcus Schmidt, Beate Rautenberg, Catarina Alisa Kunze, Uwe Rhein, Keyur Mehta, Kelly Mousa, Tessa Dibble, Xiao Lou Lu, Gϋnter von Minckwitz, Judith M. Bliss, Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators, Viktoria Tierbach, Richard Bogle, Philip Badman, Mark Churn, Jacqueline C. Newby, Elmar Stickeler, Helen Tranter, Scott Nichol, Matthew Winter, Ludger Barthelmes, Andrew Wardley, Amitabha Chakrabarti, U. Barthakur, Denise Hrouda, Pippa J Riddle, Alan L. Stewart, Chiara Intrivici, Nawaz Walji, Laura Pettit, S.C. Lupton, Pamela Woodings, Sekharan Chandrasekharan, William Maxwell, Andrew Simmonds, Rakesh Mehra, Medy Tsalic, Girija Anand, R. Allerton, Ketan Shah, Dimitri Hadjiminas, JaneMaree Maher, A.S. Dhadda, Lubna Bhatt, Ramachandran Venkitaraman, Anup Vinayan, Amanda Taylor, M. Hatton, Elin Jones, Karen McAdam, Claudia Harding-Mackean, Mark Harries, S. H. Da Silva, Mojca Persic, Jayant S. Vaidya, Anne Rigg, Lynda Wyld, Hisham Hamed, Omar S Shujja-Ud-Din, Richard Webster, Duncan Wheatley, Mariam Jafri, Abdulla Alhasso, Shazza Rehman, Simon Waters, Judith Fraser, Richard L. Hayward, J. Abraham, Helen Passant, Judy W. King, Vanessa Pope, Anthony Skene, Lucy Scott, Majory K Maclennan, Daniel Rea, N C Levitt, Sarah Khan, A Hönig, Bettina Müller, Gerhard Deutsch, Claus Hanusch, Nadia Harbeck, Sabine Lemster, Thomas Klein, Toralf Reimer and 134 more - JAMA Oncology 2021 cited by 47

  19. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

    Authors: Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes‐Davies, Adrian Harnett, Mei-Lin Ah-See, Richard Simcock, Daniel Rea, Sanjay Raj, Pamela Woodings, Mark Harries, Donna Howe, Kerry Raynes, Helen Higgins, Maggie Wilcox, Chris Plummer, Janine Mansi, Ioannis Gounaris, Betania Mahler‐Araujo, Elena Provenzano, Anita Chhabra, Jean Abraham, Carlos Caldas, Peter S Hall, Christopher McCabe, Claire Hulme, David Miles, Andrew Wardley, David Cameron, Janet Dunn, Roshan Agarwal, Hafiz Algurafi, R. Allerton, Caroline Archer, Anne Armstrong, C. Bale, Lisa Barraclough, U. Barthakur, C. Bedi, Kim Benstead, David Bloomfield, Rebecca Bowen, Chris Bradley, Jane Brown, Mohammad Butt, Mark Churn, Susan Cleator, Joanne Cliff, Perric Crellin, Margaret Daly, Shiroma De Silva-Minor, A.S. Dhadda, Omar Din, Sue Down, Helena Earl, David Eaton, Andrew Eichholz, Daniel Epurescu, Chee Goh, Andrew Goodman, Robert Grieve, Maher Hadaki, Catherine Harper‐Wynne, Mark Harries, Larry Hayward, Alison Humphreys, Helen Innes, Mariam Jafri, A. Jegannathen, Muireann Kelleher, Hartmut Kristeleit, Daniela Lee, Susan Lupton, Carol MacGregor, Zafar Malik, Janine Mansi, Jennifer Marshall, Karen McAdam, Trevor McGolick, Rakesh Mehra, David Miles, Natasha Mithal, Charlotte Moss, Aian Moss, Mukesh Mukesh, Anthony Neal, D. Nelmes, Helen Neville-Webbe, Jacqueline C. Newby, Susan O'Reilly, Peter Ostler, Mojca Persic, Laura Pettit, Sanjay Raj, Fharat Raja, Daniel Rea, Catherine Reed, Anne Rigg and 17 more - The Lancet 2019 cited by 283

  20. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

    Authors: Alistair Ring, Lucy Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr, Andrew Wardley, Bora Gürel, Iain R. Macpherson, Ruth Riisnaes, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew Winter, Kathryn Dunne, Ellen Copson, Tamas Hickish, Russell Burcombe, Kat Randle, Violeta Serra, Alba Llop‐Guevara, Judith M. Bliss, Nicholas C. Turner - Clinical Cancer Research 2023 cited by 36

  21. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Authors: Luca Gianni, Anna Lladó, Giulia Bianchi, Javier Cortés, Pirkko‐Liisa Kellokumpu‐Lehtinen, David Cameron, David Miles, Stefania Salvagni, Andrew Wardley, J. Goeminne, Veronica Hersberger, José Baselga - Journal of Clinical Oncology 2010 cited by 269

  22. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

    Authors: Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, Laurence Hogge, Matt Scullion, István Láng, Andrew Wardley, Mikhail Lichinitser, Roberto Sánchez, Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron - The Lancet Oncology 2013 cited by 211

  23. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    Authors: Thomas Bachelot, Eva Ciruelos, Andreas Schneeweiß, Fabio Puglisi, Tamar Peretz‐Yablonski, Igor Bondarenko, Shani Paluch–Shimon, Andrew Wardley, Jean-Louis Merot, Yolande Du Toit, V. Easton, Nicolas Lindegger, David Miles, Kamel Bouzid, Mario Campone, Bruno Coudert, Zbigniew Nowecki, Hassan Errihani, Florence Dalenc, Ana Ferreira, Max S. Mano, Francesco Ricci, Haralabos P. Kalofonos, Claudia Andreetta, Filippo Montemurro, Sophie Barrett, Qingyuan Zhang, Dimitris Mavroudis, Juan Antonio Matus, Carlos Beato, Xichun Hu, Rabab Gaafar, Hamdy Abdel Azeem, Christophe Perrin, Johannes Ettl, István Láng, Sunil Verma, Huiping Li, Étienne Brain, Oliver Hoffmann, Anna Cariello, Carlo Tondini, Taher Altwegeiri, Niklas Loman, Michael P. Lux, Antonio Frassoldati, Zeba Aziz, Fernando Palacios Salas, Joanna Streb, A Wroński, Salomón Menjón Beltrán, İrfan Çiçin, Peter Schmid, Robert Laing, Zhongsheng Tong, Katalin Boér, Balázs Juhász, Luca Gianni, Giuseppe Curigliano, Alejandro Juarez, Sneẑana Šušnjar, Erika Matos, Rüçhan Uslu, Hans Wildiers, Marcelo Cruz, Hugues Bourgeois, Raquel von Schumann, Salomon M. Stemmer, Flavia Morales Vásquez, Adriana Domínguez, Marek Z. Wojtukiewicz, Jasna Trifunović, José Juan Illarramendi, Laura García, Y. Izarzugaza Perón, María José Echarri, Natliia Voitko, Duncan Wheatley, Simon Waters, Richard de Boer, Guy Jérusalem, Véronique Cocquyt, Carlos H. Barrios, Lawrence Panasci, Johanna Mattson, Minna Tanner, M. Gozy, G. Vasilopoulos, János Révész, Luciano Latini, Cesare Gridelli, Jesus Miguel Lazaro, Antonio González, A. Barnadas Molins, Eduardo Martinez, Jesús Alarcón, Ana Arance, Leif Klint, Oleksiy Kovalyov, Richard D. Baird and 193 more - Annals of Oncology 2019 cited by 113

  24. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Authors: Ian Smith, Marion Procter, Richard D. Gelber, Sébastien Guillaume, A. Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, José Baselga, Manfred Kaufmann, David Cameron, Richard H. Bell, Jonas Bergh, Robert L. Coleman, Andrew Wardley, Nadia Harbeck, R.I. Lopez, Peter Mallmann, Karen A. Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez‐Rovira, Martine Piccart - The Lancet 2007 cited by 1,511